Ticker brief
KLRA
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
12
authors 14d
3
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-20 → 2026-07-02 · now +0.30 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 10 | +0.00 |
| @semodough | C | -0.75 | 1 | +0.00 |
| @ResearchPulse1 | B | +0.50 | 1 | +0.45 |
Recent signals12of 12 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @bioinvestor24 | +0.30 | Author says Medicare obesity program is a huge push for LLY and NVO and will benefit VKTX and KLRA. | · | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | +0.30 | Sees obesity challenger potential but criticizes ABBV allocation and some molecules. | · | tweet ↗ |
| 2026-06-28 | @ResearchPulse1 | +0.45 | Compares GLP-1 production economics and says KLRA rights are central versus VKTX COGS limits. | · | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | -0.35 | Bullish VKTX sc GLP1/GIP; skeptical of oral hype and KLRA tolerability. | · | tweet ↗ |
| 2026-06-27 | @bioinvestor24 | -0.20 | Highlights LLY retatrutide efficacy and says KLRA needs US data, with deal context. | · | tweet ↗ |
| 2026-06-27 | @semodough | +0.00 | Highlights research arguing VK2735 is positioned as a better tirzepatide due to backbone, activity and half-life. | · | tweet ↗ |
| 2026-06-26 | @bioinvestor24 | +0.35 | Says obesity biotechs are undervalued, comparing KLRA and GPCR deal dynamics. | · | tweet ↗ |
| 2026-06-24 | @bioinvestor24 | -0.10 | Mentions volume story in VKTX and weak volume in KLRA/GPCR possibly hiding news. | · | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | -0.15 | Speculates ABBV obesity BD interest leaves VKTX/KLRA/GPCR in play, with VKTX preferred. | · | tweet ↗ |
| 2026-06-23 | @bioinvestor24 | -0.30 | VKTX volume and drug quality seen superior to KLRA, with GLP-1 Medicare access as tailwind. | · | tweet ↗ |
| 2026-06-22 | @bioinvestor24 | +0.20 | Discusses obesity M&A scarcity and expects ABBV ultimately to pull a massive obesity deal. | · | tweet ↗ |
| 2026-06-20 | @bioinvestor24 | -0.05 | Compares oral obesity peptide programs and delivery challenges across KLRA, NVO, LLY, VKTX, GPCR. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.